Cargando…

Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body

[Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Niloy, Ghosh, Biswajit, Roy, Debadrita, Bhaumik, Biswajit, Roy, Mahendra Nath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689913/
https://www.ncbi.nlm.nih.gov/pubmed/33251458
http://dx.doi.org/10.1021/acsomega.0c04716
_version_ 1783613959563116544
author Roy, Niloy
Ghosh, Biswajit
Roy, Debadrita
Bhaumik, Biswajit
Roy, Mahendra Nath
author_facet Roy, Niloy
Ghosh, Biswajit
Roy, Debadrita
Bhaumik, Biswajit
Roy, Mahendra Nath
author_sort Roy, Niloy
collection PubMed
description [Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized by (1)H nuclear magnetic resonance ((1)H NMR), Fourier transform infrared (FTIR) spectroscopy, electrospray ionization (ESI) mass spectrometry, DSC, and fluorescence spectroscopic studies. Job’s plot provides a stoichiometric ratio of 1:1 and the Benesi–Hildebrand double reciprocal plot gives binding constant values using fluorescence spectroscopic titrations and the ESI mass data support the experimental observations. The results of molecular modeling were systematically analyzed to validate the inclusion complexation. In preliminary computational screening, α-cyclodextrin IC of umbelliferone was found to be quite stable based on the docking score, binding free energies, and dynamic simulations. In addition, the results obtained from (1)H NMR and FTIR spectroscopy studies supported the inclusion complexation phenomenon. The results obtained from computational studies were found to be consistent with the experimental data to ascertain the encapsulation of umbelliferone into α-cyclodextrin.
format Online
Article
Text
id pubmed-7689913
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-76899132020-11-27 Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body Roy, Niloy Ghosh, Biswajit Roy, Debadrita Bhaumik, Biswajit Roy, Mahendra Nath ACS Omega [Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized by (1)H nuclear magnetic resonance ((1)H NMR), Fourier transform infrared (FTIR) spectroscopy, electrospray ionization (ESI) mass spectrometry, DSC, and fluorescence spectroscopic studies. Job’s plot provides a stoichiometric ratio of 1:1 and the Benesi–Hildebrand double reciprocal plot gives binding constant values using fluorescence spectroscopic titrations and the ESI mass data support the experimental observations. The results of molecular modeling were systematically analyzed to validate the inclusion complexation. In preliminary computational screening, α-cyclodextrin IC of umbelliferone was found to be quite stable based on the docking score, binding free energies, and dynamic simulations. In addition, the results obtained from (1)H NMR and FTIR spectroscopy studies supported the inclusion complexation phenomenon. The results obtained from computational studies were found to be consistent with the experimental data to ascertain the encapsulation of umbelliferone into α-cyclodextrin. American Chemical Society 2020-11-13 /pmc/articles/PMC7689913/ /pubmed/33251458 http://dx.doi.org/10.1021/acsomega.0c04716 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Roy, Niloy
Ghosh, Biswajit
Roy, Debadrita
Bhaumik, Biswajit
Roy, Mahendra Nath
Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title_full Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title_fullStr Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title_full_unstemmed Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title_short Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
title_sort exploring the inclusion complex of a drug (umbelliferone) with α-cyclodextrin optimized by molecular docking and increasing bioavailability with minimizing the doses in human body
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689913/
https://www.ncbi.nlm.nih.gov/pubmed/33251458
http://dx.doi.org/10.1021/acsomega.0c04716
work_keys_str_mv AT royniloy exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody
AT ghoshbiswajit exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody
AT roydebadrita exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody
AT bhaumikbiswajit exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody
AT roymahendranath exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody